Study of safusidenib for grade 2 glioma with IDH1 mutation
Part of Cancer clinical trials.
This trial tests an experimental pill called safusidenib for people with a slow-growing brain tumor (grade 2 glioma) that has an IDH1 mutation. The goal is to see if it can control the tumor and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a slow-growing brain tumor (grade 2) that has a specific change called IDH1 mutation.
- You have had surgery for the tumor (at least a biopsy) within the past 5 years.
- You have not had any other cancer treatment like chemotherapy or radiation.
- You are expected to live at least 12 more months.
- You have some tumor left that can be seen on an MRI scan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial tests safusidenib, a targeted medicine, to help stop or slow the return of certain brain tumors with an IDH1 mutation. It focuses on people after initial treatment (surgery and/or radiation and temozolomide), aiming to improve outcomes during maintenance therapy.
This trial tests a new targeted therapy called safusidenib for people whose brain tumor (glioma) has an IDH1 mutation and who have already taken vorasidenib but the tumor kept growing. The study aims to see if safusidenib can help when vorasidenib stops working.
This trial tests a combination of two oral medications, olutasidenib and temozolomide, for people with a specific type of aggressive brain tumor (high-grade glioma) that has an IDH1 mutation. The goal is to see if this combination can help control the tumor after standard treatment like radiation.
This Phase 1/2 trial tests a study treatment for children and young adults under 22 whose brain glioma has come back or isn’t responding to prior treatment. It’s designed to see whether the treatment is safe and effective for shrinking tumors in this situation.
This Phase 2 study tests a combination of chemotherapy and radiation after surgery for certain brain tumors that are “IDH wildtype.” It aims to control the tumor and improve outcomes for people with specific types of glioma or glioblastoma.
This trial tests a drug called safusidenib, which targets a specific genetic change (IDH1 mutation) in certain grade 3 brain tumors. The drug is given as a pill and may help slow or stop tumor growth, especially when started early.
Hear when a new Astrocytoma, IDH-Mutant, Grade 2 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.